Denver Nephrologists PC, Denver, Colorado;, †Center for Observational Research, Amgen, Inc., Seattle, Washington, ‡Outcomes Insights, Inc., Westlake Village, California.
Clin J Am Soc Nephrol. 2013 Dec;8(12):2132-40. doi: 10.2215/CJN.04260413. Epub 2013 Sep 19.
Parathyroid hormone, calcium, and phosphate have been independently associated with cardiovascular event risk. Because these parameters may be on the same causal pathway and have been proposed as quality measures, an integrated approach to estimating event risks is needed.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Prevalent dialysis patients were followed from August 31, 2005 to December 31, 2006. A two-stage modeling approach was used. First, the 16-month probabilities of death and composite end point of death or cardiovascular hospitalization were estimated and adjusted for potential confounders. Second, patients were categorized into 1 of 36 possible phenotypes using average parathyroid hormone, calcium, and phosphate values over a 4-month baseline period. Associations among phenotypes and outcomes were estimated and adjusted for the underlying event risk estimated from the first model stage.
Of 26,221 patients, 98.5% of patients were in 22 groups with at least 100 patients and 20% of patients were in the reference group defined using guideline-based reference ranges for parathyroid hormone, calcium, and phosphate. Within the 22 most common phenotypes, 20% of patients were in groups with significantly (P<0.05) higher risk of death and 54% of patients were in groups with significantly higher risk of the composite end point relative to the in-target reference group. Increased risks ranged from 15% to 47% for death and from 8% to 55% for the composite. More than 40% of all patients were in the three largest groups with elevated composite end point risk (high parathyroid hormone, target calcium, and high phosphate; target high parathyroid hormone, target calcium, and high phosphate; and target high parathyroid hormone, target calcium, and target phosphate).
After adjusting for baseline risk, phenotypes defined by categories of parathyroid hormone, calcium, and phosphate identify patients at higher risk of death and cardiovascular hospitalization. Identifying common high-risk phenotypes may inform clinical interventions and policies related to quality of care.
甲状旁腺激素、钙和磷与心血管事件风险独立相关。由于这些参数可能处于相同的因果途径上,并被提出作为质量指标,因此需要采用综合方法来估计事件风险。
设计、设置、参与者和测量:从 2005 年 8 月 31 日至 2006 年 12 月 31 日,对现患透析患者进行随访。采用两阶段建模方法。首先,估计 16 个月的死亡率和死亡或心血管住院的复合终点的概率,并对潜在混杂因素进行调整。其次,使用 4 个月基线期的平均甲状旁腺激素、钙和磷值,将患者分为 36 种可能表型中的 1 种。使用从第一模型阶段估计的潜在事件风险来估计表型与结局之间的关系,并进行调整。
在 26221 例患者中,98.5%的患者分为至少 100 例患者的 22 个组,20%的患者为使用甲状旁腺激素、钙和磷的基于指南的参考范围定义的参考组。在 22 个最常见的表型中,20%的患者组死亡风险显著(P<0.05)更高,54%的患者组复合终点风险显著更高与目标参考组相比。死亡风险从 15%到 47%不等,复合终点风险从 8%到 55%不等。超过 40%的所有患者均处于三个复合终点风险升高的最大组(高甲状旁腺激素、目标钙和高磷;目标高甲状旁腺激素、目标钙和高磷;目标高甲状旁腺激素、目标钙和目标磷)。
在校正基线风险后,由甲状旁腺激素、钙和磷分类定义的表型可识别死亡和心血管住院风险较高的患者。确定常见的高风险表型可以为与护理质量相关的临床干预和政策提供信息。